Cholangiocarcinoma News

The Role of Liquid Biopsy in CCA

Videos — September 24, 2021

Featuring:

Jesús Bañales, PhD
Biodonostia Institute
Pamplona, Spain
Antoine Hollebecque, MD
Gustave Roussy Cancer Center
Paris, France
Milind M. Javle, MD
Hubert L. and Olive Stringer Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas
M.D. Anderson Cancer Center
Houston, TX
Chair
NCI Task Force: Hepatobiliary Cancers
Angela Lamarca, MD, PhD, MSc
Consultant (FEA) in Medical Oncology
HPB-NET–Gastrointestinal Tumors Group, Department of Oncology
Fundación Jiménez Díaz University Hospital
Autonomous University of Madrid
Madrid, Spain
Drs Javle, Bañales, and Lamarca provide their perspectives on the advantages and disadvantages of liquid biopsy in identifying genomic alterations to direct targeted therapy, avoiding the need for more invasive tissue biopsy, and tracking resistance and tumor mutational evolution in CCA, both in clinical studies and in practical use in real-world settings.

Related Items

Annual CCF Conference Brings Together All Stakeholders
By Milind M. Javle, MD
June 2023, Vol 4, No 2
This issue of CCA News highlights the Cholangiocarcinoma Foundation (CCF) 10th Annual Conference held in April. This meeting was chaired by Dr Chiara Branconi, a Lord Kelvin Adam Smith Reader at the University of Glasgow and a medical oncologist with Beatson Cancer Centre; and Dr Laura Goff, medical director of the Vanderbilt-Ingram Cancer Center’s Hematology and Oncology Division.
Exciting New Abstracts from the ASCO GI Cancers Symposium
By Milind M. Javle, MD
March 2023, Vol 4, No 1
Dr Javle provides his perspective on important abstracts presented at the ASCO Gastrointestinal Cancers Symposium, held January 19-21, 2023, in San Francisco, CA.
Highlights from the Fourth Annual CCA Summit
By Milind M. Javle, MD
December 2022, Vol 3, No 4
We have recently concluded the 4th Annual CCA Summit, which was held on October 13-15, 2022, in Denver, Colorado.
New Standard of Care Emerging for Treatment of BTCs
By Milind M. Javle, MD
September 2022, Vol 3, No 3
On September 2, 2022, the US Food and Drug Administration approved durvalumab in combination with gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) on the basis of the TOPAZ-1 study.
CCA Summit Live from ESMO GI 2022
By Angela Lamarca, MD, PhD, MSc
Videos
Angela Lamarca, MD, PhD, MSc, Consultant (FEA) in Medical Oncology presents an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2022 annual meeting of the ESMO World Congress on Gastrointestinal Cancer (ESMO GI 2022).
Rapid Trajectory of Clinical Research in Biliary Tract Cancers
By Milind M. Javle, MD
March 2022, Vol 3, No 1
The 2022 ASCO GI Cancers Symposium clearly highlighted the rapid trajectory of clinical research in biliary tract cancers. One of the most eagerly anticipated studies, TOPAZ-1, was presented by Do-Youn Oh, MD, PhD, from Seoul National University Hospital in South Korea. This phase 3 clinical trial enrolled 685 patients and investigated the addition of the PD-L1–directed agent durvalu­mab to gemcitabine and cisplatin chemotherapy backbone versus these chemotherapies alone. The results demonstrated a statistically significant improvement in overall survival (OS), overall response rate (ORR), and progression-free survival (PFS), without dose-limiting toxicities.
Hot Topics at ASCO-GI 2022
By Milind M. Javle, MD
Videos
Dr Milind Javle provides his perspectives on key presentations on cholangiocarcinoma and biliary tract cancer at the 2022 ASCO Gastrointestinal Cancers Symposium.
Cholangiocarcinoma Research Continues to Thrive
By Milind M. Javle, MD
December 2021, Vol 2, No 4
The Third CCA Summit was held on October 21-22, 2021 in New Orleans. For the majority of the cholangiocarcinoma (CCA) community, this was their first “live” meeting since the pandemic.
Advances in Translational Biology and Molecular Targets in CCA
By Jesús Bañales, PhD
Videos
Dr Jesus Bañales discusses advances in our understanding of molecular targets that can be used to direct therapy against novel molecular pathways in CCA.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: